Formulari Ubat KKM (FUKKM)

# Generic Name MDC Category Indications Pres. Restrictions Dosage
1051 Mometasone Furoate 0.1% Cream D07AC13139G1001XX A/KK For the relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses None Apply thin layer to the affected skin areas once daily until the lesion heals or for a duration of 3 weeks whichever is sooner. Massage gently and thoroughly until the medication disappears.
1052 Mometasone Furoate 0.1% Lotion D07AC13-139-L60-01-xxx A* For the relief of the inflammatory and pruritic manifestations of the corticosteroid responsive dermatoses None Apply a few drops to affected skin areas including scalp sites once daily; massage gently and thoroughly until the medication disappears.
1053 Mometasone Furoate 0.1% Ointment D07AC13-139-G50-01-XXX A/KK For the relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses None Apply thin layer to the affected skin areas once daily until the lesion heals or for a duration of 3 weeks whichever is sooner. Massage gently and thoroughly until the medication disappears.
1054 Mometasone Furoate 50mcg Aqueous Nasal Spray R01AD09-139-A41-01-XX A* i) Allergic rhinitis.
ii) For the treatment of nasal polyps in patients 18 years of age and older.		 None ALLERGIC RHINITIS: ADULT and CHILD, 12 years and above: 100 mcg/day (2 sprays) to each nostril once daily. Maximum 200 mcg (4 sprays) once daily. Reduce to 50 mcg (1 spray) once daily when control achieved.
CHILD 3 - 11 years old: 50 mcg (1 spray) to each nostril once daily.

TREATMENT OF NASAL POLYPS: Two sprays (50 micrograms/spray) in each nostril twice daily (total daily dose of 400 mcg). Once symptoms are adequately controlled, dose reduction to two sprays in each nostril once daily (total daily dose 200 mcg) is recommended.
1055 Monobasic Sodium Phosphate 48%, Dibasic Sodium Phosphate 18% A06AG01162L5001XX A Bowel cleansing prior to colonoscopy, radiological examination or bowel surgery 45 ml diluted with half a glass (120 ml) of water, followed by one full glass (240 ml) of water to be taken depending on the time of the procedure. For morning procedure, 45 ml dilute with half glass of water should be taken at 7 am and the second 45 ml at 7 pm on the day before the procedure. For afternoon procedure, the first dose should be taken at 7 pm on the day before and the second dose at 7 am on the day of the procedure. Solid food must not be taken during the preparation period; clear fluids or water can be taken liberally. Not recommended for use in children
1056 Montelukast Sodium 10 mg Tablet R03DC03-520-T10-01-XX A/KK Chronic treatment of asthma and relief of symptoms of seasonal allergic rhinitis for children more than 15 years and adults None CHILD more than 15 years and ADULT: 10 mg daily at bedtime
1057 Montelukast Sodium 4mg Oral Granules R03DC03-520-F10-01-XXX A* Asthmatics, not controlled on high dose inhaled corticosteroids more than 1600 mcg/day and with co-morbid allergic disorders. Chronic treatment of asthma None 12 months - 5 years: 1 packet of 4mg oral granules daily at bedtime
1058 Montelukast Sodium 5mg Tablet R03DC03-520-T20-01-XXX A* Asthmatics, not controlled on high dose inhaled corticosteroids more than 1600 mcg/day and with co-morbid allergic disorders. Chronic treatment of asthma None CHILD 6 - 14 years: One 5 mg chewable tablet daily at bedtime
1059 Morphine Sulphate 10mg Prolonged Release Tablet N02AA01-183-T50-01-XXX A, A/KK Category Prescriber A/KK:
i) Prolonged relief of severe pain associated with neoplastic disease

Category Prescriber A:
ii) As a second line treatment of chronic non-cancer pain when treatments with adjuvant analgesics and non-pharmacological approach failed		 Indication (i):
Category Prescriber A/KK: To be prescribed by Family Medicine Specialists trained in pain management

Indication (ii):
Initiated by Pain or Palliative Specialists only		 10 - 60 mg 12 hourly intervals, depend upon the severity of the pain.
Children (more than 1 year of age) with severe cancer pain: 0.2 - 0.8mg/kg 12 hourly.
1060 Morphine Sulphate 10mg Suppository N02AA01-183-S20-01-XXX A* Relief of severe chronic pain (cancer patient) None 15 - 30 mg regularly every 4 hours
1061 Morphine Sulphate 10mg/ml Injection N02AA01-183-P30-01-XXX B i) For moderate to severe pain especially that associated with neoplastic disease

ii) As an analgesic adjunct in general anaesthesia.		 None ADULT:
5 to 20 mg every 4 hours, intravenously (IV or IM), 2.5 to 15mg should be given by slow injection.

CHILD:
- Adjusted according to body weight, 0.1 – 0.2 mg /kg every 4 hours. No dose should exceed 15 mg.
- Analgesic
Indication (i) subcutaneous, 100 mcg to 200 mcg (0.1 to 0.2 mg) per kg of body weight every four hours as needed, not to exceed 15mg per dose.

Indication (ii) Intravenous, 50 to 100 mcg (0.05 mg to 0.1 mg) per kg of body weight, administered very slowly.
1062 Morphine Sulphate 20 g Suppository N02AA01-183-S20-02-XXX A* Relief of severe chronic pain (cancer patient) None 15 - 30 mg regularly every 4 hours
1063 Morphine Sulphate 30mg Prolonged Release Tablet N02AA01-183-T50-02-XXX A i) Prolonged relief of severe pain associated with neoplastic disease

ii) As a second line treatment of chronic non-cancer pain when treatments with adjuvant analgesics and non-pharmacological approach failed		 Indication (ii)
Initiated by Pain or Palliative Specialists only		 10 - 60 mg 12 hourly intervals, depend upon the severity of the pain
1064 Morphine Sulphate 30mg Suppository N02AA01-183-S20-03-XXX A* Relief of severe chronic pain (cancer patient) None 15 - 30 mg regularly every 4 hours
1065 Morphine Sulphate 5mg Immediate Release Tablet N02AA01-183-T60-01-XXX A* Relief of moderate to severe pain (cancer patient) None 5-10 mg every four hours. The dose may be increased according to needs
1066 Morphine Sulphate 60mg Prolonged Release Tablet N02AA01-183-T50-03-XXX A i) Prolonged relief of severe pain associated with neoplastic disease

ii) As a second line treatment of chronic non-cancer pain when treatments with adjuvant analgesics and non-pharmacological approach failed		 Indication (ii):
Initiated by Pain or Palliative Specialists only		 10 - 60 mg 12 hourly intervals, depend upon the severity of the pain.
Children (more than 1 year of age) with severe cancer pain: 0.2 - 0.8mg/kg 12 hourly.
1067 Moxifloxacin 0.5% Ophthalmic Solution S01AX22-110-D20-01-XXX A* Treatment of conjunctivitis caused by susceptible organism None CHILD more than 1 year and ADULT: 1 drop to affected eye(s) 3 times daily for 7 days
1068 Moxifloxacin 400 mg Injection J01MA14110P3001XX A* Second line therapy for Severe Community Acquired Pneumonia (CAP) patients with co-morbidity or with recent antibiotic therapy, suspected infections of resistant pathogens including Streptococcus pneumoniae, Haemophilus influenzae & Mycoplasma pneumoniae. IV or Oral: 400 mg once daily. The recommended total treatment duration for sequential administration (intravenous followed by oral therapy) is 7 to 14 days
1069 Moxifloxacin 400mg Tablet J01MA14110T1001XX A* Second line therapy for Severe Community Acquired Pneumonia (CAP) patients with co-morbidity or with recent antibiotic therapy, suspected infections of resistant pathogens including Streptococcus pneumoniae, Haemophilus influenzae & Mycoplasma pneumoniae. IV or Oral: 400 mg once daily. The recommended total treatment duration for sequential administration (intravenous followed by oral therapy) is 7 to 14 days
1070 Multivitamin Drops A11BA00901D5001XX B For prevention and treatment of vitamin deficiencies INFANT less than 1 year: 1 ml daily
1071 Multivitamin Injection A11BA00901P3001XX B For prevention and treatment of vitamin deficiencies Initially 2 - 4 pairs IV 4 - 8 hourly, reducing to 1 pair IV daily. For less serious cases, 1 pair IV 1 - 2 times daily or based on individual requirements
1072 Multivitamin Syrup A11BA00901L9001XX C+ For prevention and treatment of vitamin deficiencies CHILD 5 ml daily or based on manufacturer
1073 Multivitamin Tablet A11BA00901T1001XX B For prevention and treatment of vitamin deficiencies 1 - 2 tablets daily or based on individual requirements
1074 Mupirocin 2% Cream D06AX09000G1001XX A Skin infection by Staphylococcus aureus (including MRSA), Staphylococcus epidermidis and beta-haemolytic streptococcus Adults and child over 1 year, apply up to 3 times daily for up to 10 days
1075 Mupirocin 2% Ointment D06AX09000G5001XX A Bacterial skin infections by Staphylococcus and Streptococcus sp. None ADULT and CHILD: Apply up to three times daily for up to 10 days
1076 Mycophenolate Mofetil 250 mg Capsule L04AA06236C1001XX A* i) Prophylaxis of acute organ rejection in patients receiving allogenic renal, cardiac and hepatic transplant
ii) Used with steroids for induction and maintenance of severe lupus nephritis		 i) Renal transplant rejection: ADULT: 1 g twice daily. CHILD (3 months and older): 600 mg/m(2)/dose, twice daily; maximum daily dose, 2 g/10 mL. Cardiac transplant rejection: 1.5 g twice daily. Hepatic transplant rejection: 1.5 g twice daily
ii) Induction phase: 2 - 3 g/day for up to 6 months. Maintenance phase: dose gradually tapers to 1 g/day
1077 Mycophenolate Mofetil 500 mg tablet L04AA06236T1002XX A* i) Prophylaxis of acute organ rejection in patients receiving allogenic renal, cardiac and hepatic transplant
ii) Used with steroids for induction and maintenance of severe lupus nephritis		 i) Renal transplant rejection: ADULT: 1 g twice daily. CHILD (3 months and older): 600 mg/m(2)/dose, twice daily; maximum daily dose, 2 g/10 mL. Cardiac transplant rejection: 1.5 g twice daily. Hepatic transplant rejection: 1.5 g twice daily
ii) Induction phase: 2 - 3 g/day for up to 6 months. Maintenance phase: dose gradually tapers to 1 g/day
1078 Mycophenolate Sodium 180mg Tablet L04AA06520T1001XX A* Prophylaxis of acute transplant rejection in adult patients receiving allogenic renal transplant in combination with ciclosporin and corticosteroids 720 mg twice daily
1079 Mycophenolate Sodium 360mg Tablet L04AA06520T1002XX A* Prophylaxis of acute transplant rejection in adult patients receiving allogenic renal transplant in combination with ciclosporin and corticosteroids 720 mg twice daily
1080 Nalbuphine HCl 10 mg/ml Injection N02AF02110P3001XX B i) Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
ii) As a supplement to balanced anesthesia, for preoperative and postoperative analgesia and for obstetrical analgesia during labor and delivery		 i) ADULT: 10mg SC, IM or IV repeated every 3-6 hours as necessary.
Max. single dose: 20mg
Max. total daily dose: 160mg

ii) Induction: 0.3 – 3 mg/kg IV to be administered over 10 to 15 min
Maintenance: 0.25 – 0.50 mg / kg in single IV administration as required.

Halaman-halaman